Clene Inc. (CLNN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Clene Inc. (CLNN) Healthcare & Pipeline Overview

Clene Inc. is a clinical-stage biotechnology firm specializing in clean-surfaced nanotechnology (CSN) therapeutics, with a primary focus on CNM-Au8, a drug candidate in Phase 2/3 trials for neurodegenerative diseases like ALS, Multiple Sclerosis, and Parkinson's Disease. The company also develops treatments for infectious diseases and wound healing.

What Is the Investment Thesis for CLNN?

Clene Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The primary value driver is the successful clinical development and regulatory approval of CNM-Au8 for ALS and other neurodegenerative diseases. Positive Phase 2/3 trial results for ALS could serve as a significant catalyst, potentially leading to accelerated approval pathways and subsequent commercialization. The company's focus on CSN therapeutics offers a differentiated approach to treating diseases with unmet needs. However, the company's negative profit margin of -13086.5% highlights the financial risks associated with clinical-stage pharmaceutical companies. The company's relatively small market capitalization of $53.5M makes it susceptible to volatility. Upcoming clinical trial readouts and regulatory milestones are key events to monitor.

Based on FMP financials and quantitative analysis

CLNN Key Highlights

Market capitalization of $53.5M indicates a small-cap company with potential for high growth but also higher risk.

• Gross margin of 78.5% suggests strong pricing power and efficient production, if and when products are commercialized.
• Profit margin of -13086.5% reflects significant ongoing R&D expenses typical of a clinical-stage biotech company.
• Beta of 0.62 indicates lower volatility compared to the overall market.
• CNM-Au8 is in Phase 2/3 clinical trials for ALS, representing a potential near-term catalyst for the company.

Who Are CLNN's Competitors?

CLNN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CLNN's Key Strengths?

Novel clean-surfaced nanotechnology (CSN) platform.

• Lead drug candidate CNM-Au8 in Phase 2/3 clinical trials.
• Focus on neurodegenerative diseases with unmet medical needs.
• Experienced management team with expertise in nanotechnology.

What Are CLNN's Weaknesses?

Clinical-stage company with no currently approved products.

• High R&D expenses and negative profit margins.
• Reliance on the success of CNM-Au8.
• Small market capitalization and limited financial resources.

What Could Drive CLNN Stock Higher?

Data readout from the Phase 2/3 clinical trial of CNM-Au8 in ALS patients.

• Initiation of Phase 2 clinical trial for CNM-Au8 in Parkinson's Disease patients.
• Enrollment and progress in the Phase 2 clinical trial for CNM-Au8 in Multiple Sclerosis patients.
• Development and potential commercialization of CNM-AgZn17 for infectious diseases and wound healing.

What Are the Key Risks for CLNN?

Financial-distress signal — its Altman Z-Score of -23.04 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure to achieve positive results in clinical trials for CNM-Au8.
• Delays in regulatory approval processes.
• Competition from larger pharmaceutical companies with greater resources.
• Dependence on securing additional funding to support ongoing operations and clinical trials.
• Challenges in protecting intellectual property and maintaining patent exclusivity.

What Are the Growth Opportunities for CLNN?

• Growth opportunity 1: Successful completion of the Phase 2/3 clinical trial for CNM-Au8 in ALS patients represents a significant growth opportunity. Positive results could lead to accelerated regulatory approval and commercialization, addressing a market with substantial unmet needs. Timeline: Anticipated data readout in the next 12-18 months.
• Growth opportunity 2: Expansion of CNM-Au8 into other neurodegenerative diseases, such as Multiple Sclerosis and Parkinson's Disease, represents another key growth driver. The company has ongoing and planned clinical trials in these indications, potentially broadening the addressable market and diversifying its product pipeline. Success in these trials could significantly increase the company's long-term growth prospects. Timeline: Ongoing clinical trials with data readouts expected in the next 24-36 months.
• Growth opportunity 3: Development and commercialization of CNM-AgZn17 for infectious diseases and wound healing offers a diversification opportunity. The market for wound care and anti-infective products is substantial, providing a potential revenue stream outside of neurodegenerative diseases. The company's nanotechnology platform could provide a competitive advantage in these areas. Timeline: Ongoing development with potential for commercialization in the next 3-5 years.
• Growth opportunity 4: Strategic partnerships with larger pharmaceutical companies could accelerate the development and commercialization of Clene's products. Collaborations could provide access to funding, expertise, and distribution channels, enhancing the company's ability to reach a broader market. Timeline: Ongoing discussions with potential partners.
• Growth opportunity 5: Expansion into new geographic markets, particularly in Europe and Asia, represents a long-term growth opportunity. These regions have a growing aging population and increasing demand for innovative therapies for neurodegenerative diseases. Establishing a presence in these markets could significantly increase the company's revenue potential. Timeline: Long-term strategic goal with potential for expansion in the next 5-7 years.

What Are CLNN's Competitive Advantages?

• Proprietary clean-surfaced nanotechnology (CSN) platform.
• Patent protection for CNM-Au8 and other drug candidates.
• Clinical trial data demonstrating potential efficacy.
• Expertise in nanotechnology and neurodegenerative diseases.

What Does CLNN Do?

Clene Inc., headquartered in Salt Lake City, Utah, is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company was founded with the goal of creating innovative treatments for neurodegenerative diseases and other conditions with unmet medical needs. Clene's lead drug candidate, CNM-Au8, is a gold nanocrystal suspension designed to enhance neuronal survival and function by improving cellular energy metabolism. CNM-Au8 is currently being evaluated in a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS), following the completion of a Phase 2 proof-of-concept clinical trial in patients with early symptomatic ALS. The company has also completed two open-label investigator-blinded Phase 2 clinical trials assessing the impact of CNM-Au8 on the brain's energy metabolites. In addition to CNM-Au8, Clene is developing CNM-AgZn17, a gel polymer suspension of silver and zinc ions, for the treatment of infectious diseases and to accelerate wound healing. The company also markets dietary supplements, including rMetx, an aqueous zinc-silver ion dietary supplement, and KHC46, an aqueous gold dietary supplement. Clene's focus on nanotechnology and neurodegenerative diseases positions it as a specialized player in the biotechnology sector.

What Products and Services Does CLNN Offer?

• Develop clean-surfaced nanotechnology (CSN) therapeutics.
• Focus on treatments for neurodegenerative diseases.
• Conduct clinical trials for CNM-Au8 in ALS, Multiple Sclerosis, and Parkinson's Disease.
• Develop CNM-AgZn17 for infectious diseases and wound healing.
• Market and distribute dietary supplements.
• Research and develop new CSN therapeutics for oncology applications.

How Does CLNN Make Money?

• Develop and patent novel CSN therapeutics.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from the FDA and other agencies.
• Commercialize approved products through direct sales and partnerships.
• Generate revenue through product sales and licensing agreements.

What Industry Does CLNN Operate In?

Clene Inc. operates within the competitive biotechnology industry, which is characterized by high R&D spending, lengthy regulatory approval processes, and significant market potential for successful therapeutics. The industry is driven by innovation in areas such as nanotechnology and precision medicine. Clene's focus on neurodegenerative diseases aligns with the growing prevalence of these conditions and the increasing demand for effective treatments. The company competes with larger pharmaceutical companies and specialized biotech firms developing therapies for similar indications. The success of Clene depends on its ability to navigate the regulatory landscape, secure funding, and demonstrate clinical efficacy.

Who Are CLNN's Key Customers?

• Patients with neurodegenerative diseases (ALS, Multiple Sclerosis, Parkinson's Disease).
• Healthcare providers (neurologists, hospitals, clinics).
• Patients seeking treatments for infectious diseases and wound healing.
• Consumers of dietary supplements.

Wall Street analysts project Clene Inc. revenue of about $207K for fiscal 2026, with EPS near $-1.79. The estimate reflects 3 contributing analysts.

Quarterly Financial Performance: Clene Inc.

Revenue for Clene Inc. came in at $90K during Q2 2026, a 500.0% improvement versus the preceding quarter. The company recorded a net loss of $13.4M, with diluted EPS of $-1.08. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, CLNN averaged $-0.89 in diluted EPS.

CLNN Valuation & Market Position

With a $53.5M market cap, Clene Inc. sits in the micro-cap segment of the market. Relative to its peer group, CLNN's quantitative score of 17/100 is below the peer average of 80/100.

Return on equity for Clene Inc. stands at 233.9%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -30.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.94 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -50.1%, the inverse of the P/E and a quick read on earnings relative to price.

Clene Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -23.04 places it in the distress zone, a signal of elevated financial risk.

Clene Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 40.7% below estimates on average.

Company Profile

Clene Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Salt Lake City, US. The company is led by CEO Robert Etherington. CLNN has traded publicly since 2018.

CLNN Financials

CLNN Latest News

CLNN Analyst Consensus

CLNN MoonshotScore

What Investors Ask About Clene Inc. (CLNN) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources